Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Century Therapeutics (NASDAQ: IPSC), a clinical-stage biotechnology firm, announced its participation in a fireside chat at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on April 24, 2023, at 10:30 AM ET. The chat will feature Greg Russotti, Ph.D., serving as the ad-interim CEO. This event underscores Century's focus on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) aimed at treating cancer. The replay will be accessible for 30 days post-event on the company’s Investors page at centurytx.com. Century Therapeutics aims to address challenges in oncology by creating off-the-shelf therapies that enhance patient access and treatment efficacy, with a commitment to superior cell therapy technologies.
Century Therapeutics (NASDAQ: IPSC) announced key executive changes as of April 11, 2023. Greg Russotti, Ph.D., formerly the Chief Technology Officer, is now serving as the ad-interim Chief Executive Officer, succeeding Lalo Flores, Ph.D., who stepped down to pursue other opportunities. Additionally, Michael C. Diem, M.D., has been promoted to Chief Financial Officer, and Hy Levitsky, M.D., has rejoined the company as President of Research and Development. The Board of Directors is actively searching for a permanent CEO. Joe Jimenez, Chairman, highlighted Dr. Russotti's clinical and commercial expertise, emphasizing his capability to advance Century’s position in the cell therapy industry. The company maintains a solid balance sheet expected to fund operations into 2026, aiming to deliver innovative allogeneic cell therapies and target various cancers.